

Rapid identification of gram-negative bacteria with and without CTX-M extended-spectrum  $\beta$ -lactamase from positive blood culture bottles by PCR followed by microchip gel electrophoresis

メタデータ	言語: eng 出版者: 公開日: 2017-10-03 キーワード (Ja): キーワード (En): 作成者: メールアドレス: 所属:
URL	<a href="http://hdl.handle.net/2297/27789">http://hdl.handle.net/2297/27789</a>

Rapid identification of Gram-negative bacteria with and without CTX-M extended-spectrum  $\beta$ -lactamase from positive blood culture bottles by PCR followed by microchip gel electrophoresis

Running title: Identification of CTX-M-producing GNB by PCR

Key words: blood culture, rapid identification, Gram-negative bacilli, microchip gel electrophoresis, extended-spectrum  $\beta$ -lactamase

Shin-ichi Fujita<sup>1\*</sup>, Kentaro Yosizaki<sup>1</sup>, Thikako Ogushi<sup>2</sup>, Kouhei Uechi<sup>2</sup>, Yukiko Takemori<sup>2</sup>, and Yasuko Senda<sup>2</sup>

Department of Laboratory Sciences, School of Health Sciences<sup>1</sup>, and Department of Clinical Laboratory, Kanazawa University Hospital<sup>2</sup>, Kanazawa University, 5-11-80, Kodatuno, Kanazawa 920-0942, Japan

Corresponding author:

Shin-ichi Fujita

Department of Laboratory Sciences, School of Health Sciences, Kanazawa University, 5-11-80, Kodatuno, Kanazawa 920-0942, Japan

TEL: +81-76-265-2006

FAX: +81-76-243-3276

e-mail: fujita-knz@umin.ac.jp

## ABSTRACT

We evaluated the usefulness of PCR analysis of the 16S-23S rRNA gene internal transcribed spacer (ITS) and CTX-M extended-spectrum  $\beta$ -lactamase (ESBL) followed by microchip gel electrophoresis (MGE) for direct identification and CTX-M detection of Gram-negative bacteria (GNB) from positive blood culture bottles. Of 251 GNB isolated from blood cultures containing a single bacterium, 225 (90%) were correctly identified at the species level directly from positive blood culture bottles by comparing the ITS-PCR patterns of the sample strain with those of the control strains. There were no cases of incorrect identification. Limitations encountered included the inability to detect mixed cultures (four bottles) as well as some species (*Enterobacter* species and *Klebsiella oxytoca*) demonstrating identical ITS-PCR patterns. One hundred nine ESBL-producing isolates from various clinical materials between January 2005 and December 2008 were examined for *bla*<sub>CTX-M</sub>, *bla*<sub>SHV</sub>, and *bla*<sub>TEM</sub> genes by PCR and sequences of PCR products. CTX-M ESBL was detected from 105 isolates and SHV ESBL from two isolates. The remaining two isolates (*K. oxytoca*) were shown to harbor *bla*<sub>oxy</sub>. Twenty (19%) of 104 *Escherichia coli* isolates from blood cultures were suspected to produce ESBL by the combination disk method, and these isolates were shown to harbor CTX-M ESBL by PCR-MGE. The results were obtained within 1.5 h at a calculated cost of \$6.50 per specimen. In conclusion, simultaneous detection of ITS length polymorphisms and *bla*<sub>CTX-M</sub> by single PCR followed by MGE is useful for rapid, cost-effective, and reliable species-level identification of CTX-M ESBL-producing GNB responsible for bloodstream infections.

## INTRODUCTION

Bloodstream infections are a major cause of morbidity and mortality. Traditional identification of blood culture isolates requires subculture and overnight incubation to obtain isolated colonies. Rapid methods to differentiate bacteria directly from positive blood cultures have been developed (7, 8, 14), thus reducing the turnaround time compared to traditional testing. Rapid identification can significantly improve outcome in infected patients by enabling rapid and appropriate antimicrobial therapy, leading to a decrease in mortality, shortened hospital stay, and lower hospitalization costs (3).

Several nucleic acid-based approaches have proven useful for identifying many microorganisms and are becoming more commonplace in the clinical microbiology laboratory (14, 21). Spacer regions separating the two prokaryotic rRNA genes are characterized by a high degree of sequence and length variation at both the genus and species levels (5, 8, 10, 13). The aim of the present study was to establish a rapid and accurate method for the identification of GNB from isolated colonies, as well as positive blood culture bottles with positive signals, by PCR amplification of the 16S-23S rRNA gene spacer region. As for rapid sizing of PCR products, Turenne et al (25) used a capillary electrophoresis system which needs less than 30 min for analysis. Recently, electrophoretic analysis with a microchip was developed (6). To determine the length of PCR products more rapidly, we used a microchip gel electrophoresis (MGE) instrument. This instrument detects PCR products within 5 min, whereas agar gel electrophoresis used in our study needed 2 h to determine the length of PCR amplicons. The former has enabled us to generate a profile of the expected amplicon sizes for a broad range of bacteria. The advantages of using such an instrument include speed and elimination of slab gels and staining steps as well as of species-specific probes or DNA sequencing.

Furthermore, minimal manual labor is required, thus making the fragment detection system accurate and cost-effective.

Earlier studies have shown that antimicrobial susceptibility testing does not significantly influence a physician's choice of appropriate antimicrobial therapy (18). However, with advances in technology PCR-based detection of *mecA* and *van* directly from positive blood culture bottles is now available (7). On the other hand, ESBL-producing strains, especially CTX-M ESBL-producing strains, are increasing worldwide (4, 9, 11, 15, 23). Although ESBLs are inactivated with  $\beta$ -lactamase inhibitors, ESBL-producing strains may be resistant to third- to fourth generation cephalosporins such as cefotaxime, ceftazidime and cefepime. Therefore, antibiotic options in the treatment of ESBL-producing organisms are limited (11, 24). In addition to rapid species identification of microorganisms, detection of the CTX-M gene in blood culture bottles was simultaneously examined by single PCR in the present study.

## MATERIALS AND METHODS

**Bacterial strains.** A total of 329 GNB (given the prefix K) isolated from clinical samples between January 2005 and December 2007 at Kanazawa University Hospital and 39 reference strains were used to determine the internal transcribed spacer PCR patterns (ITS-PCR). The reference strains were obtained from the American Type Culture Collection (ATCC) (Manassas, VA), NITE Biological Resource Center (NBRC) (Tokyo, Japan), Laboratory Culture Collection (IID) (University of Tokyo, Tokyo, Japan), and the Japan Collection of Microorganisms (JCM) (Wako, Japan) (Table 1). In addition, isolates of clinically relevant species not included in the reference strains were selected from the isolates from our laboratory, and used as controls. When two or more ITS-PCR

patterns were found among the same species, a strain isolated at Kanazawa University Hospital was selected randomly from each group of ITS-PCR pattern and was also used as a control.

A total of 255 blood culture bottles (259 isolates) that gave positive results on testing for GNB from January 2007 to December 2009 were used for molecular identification of bacteria by ITS-PCR and for detection of CTX-M ESBL by PCR. Our laboratory uses the BacT/ALERT 3D blood culture system (bioMérieux Inc., Durham, NC) with SA aerobic and SN anaerobic bottles. For each positive blood culture, 5% sheep blood agar, Drigalski agar, and Brucella HK agar (only for isolation of anaerobes) were inoculated with a drop of broth for isolation. All strains were identified by colony morphology, Gram stain characteristics, oxidase test, and by using commercially available kits, such as API 20E (bioMérieux) for *Enterobacteriaceae*, ID test NF-18 (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) for glucose non-fermenting GNB, and ID test HN-20 (Nissui) for *Haemophilus* and *Neisseria* species. The *Bacteroides fragilis* group was identified presumptively by growth on both *Bacteroides* agar plate (Nissui) and *Bacteroides* bile esculin agar plate (Kyokuto Pharmaceutical Ind., Co., Ltd., Tokyo), and *Fusobacterium* species by growth on a modified FM agar plate (Nissui).

#### **DNA preparation.**

A colony grown on modified Drigalski agar was suspended in 0.2 ml of TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) at a density equivalent to a 0.5 McFarland standard. Aliquots of 2  $\mu$ l of proteinase K solution (20 mg/ml) (Takara Shuzo Co., Ltd., Ohtsu, Japan) were added, followed by incubation at 60°C for 5 min. After 7 min of incubation in a boiling water bath, the lysate was centrifuged at  $9,000 \times g$  for 2 min, and the

supernatant was used as the template DNA. Processing of positive blood culture bottles for PCR was performed as described previously (8) with slight modifications. Briefly, ~10 ml of 0.1% sodium dodecyl sulfate was added to 0.1 to 0.2 ml of blood culture fluids, and the mixtures were centrifuged at  $4,000 \times g$  for 10 min. The pellets were suspended in 1.5 ml of distilled water and centrifuged again at  $9000 \times g$  for 1 min. Then, 0.1 ml of TE buffer and 2  $\mu$ l of proteinase K solution were added to the pellet, and the mixture was incubated at 60°C for 5 min. After 7 min of incubation in a boiling water bath, the lysate was centrifuged at  $9,000 \times g$  for 2 min, and the supernatant was used as the template DNA. DNA was extracted from isolated colonies in ~20 min and that from GNB-positive blood culture bottles was obtained in ~30 min.

#### **Identification of GNB by ITS-PCR.**

ITS-PCR was performed using the bacterium-specific universal primers IX (5'-GGTGAAGTCGTAACAAG-3') and II (5'-TGCCAAGGCATCCACC-3') (8). PCR was performed with 1.5  $\mu$ l of the template DNA in a total reaction volume of 30  $\mu$ l consisting of 0.75 U of *Z-Taq* DNA polymerase (Takara Bio Inc., Shiga, Japan), 0.1  $\mu$ M each primer, 0.2 mM each deoxynucleoside triphosphate, and 3 mM  $MgCl_2$ . Reactions were run in a thermocycler (Biometra Co., Göttingen, Germany). The PCR program consisted of 95°C for 10 s (first cycle only), 99°C for 8 s, 52°C for 12 s, 72°C for 20 s (25 cycles), and a final extension step at 72°C for 5 min. The ESBL genes were also amplified by PCR. The PCR products were separated with MGE instrument (model SV1200; Hitachi Electronics Engineering Co., Ltd., Tokyo, Japan) as described previously (8). Briefly, a mixture of 9  $\mu$ l of PCR product and 1  $\mu$ l of loading buffer containing the internal standards was loaded into one of the sample

wells of the microchip, and the mixture was run for 5 min. The mixture of ITS-PCR and CTX-M PCR products was applied to MGE, and the electrophoresis patterns were analyzed. The database for ITS-PCR patterns of GNB was constructed by using commercially available database soft, File Maker Pro (FileMaker Inc. Santa Clara, CA). When one to five sizes of PCR products in the order from shorter one were input into the database, the names of organism which showed the similar ITS-PCR patterns with test strain was shown automatically and the ITS-PCR pattern of the test strain was compared visually with those of the control strains on the computer screen. Identification was assigned to those isolates with ITS-PCR patterns that matched any of the control strains. The PCR procedure required ~40 min, and MGE took ~5 min. Therefore, the overall turnaround time of the PCR-MGE was ~1.5 h with positive blood culture bottles.

#### **Detection of ESBLs.**

One hundred sixteen of 2,216 *Enterobacteriaceae* strains isolated from various clinical samples between January 2005 and December 2008 were shown to be insusceptible (intermediate or resistant) to cefotaxime, cefoperazone, or ceftazidime by the disk diffusion method. These antibiotic-nonsusceptible isolates were further subjected to analysis for ESBLs. Phenotypic test for ESBL production was performed according to the Clinical and Laboratory Standards Institute (CLSI) recommended method using combination disks (19). The disks used were cefotaxime, cefpodoxime, and ceftazidime disks with and without clavulanate (Eiken Chemical Co., Ltd., Tokyo). *Klebsiella pneumoniae* ATCC 70063 was used as a control SHV ESBL-positive strain, and *Escherichia coli* ATCC 35218 was used as a *bla*<sub>TEM-1</sub>-positive strain. Fifty-three



ESBL-non-producing *Enterobacteriaceae* strains isolated in our laboratory were also used as negative controls. PCR was performed under the same conditions as described for ITS-PCR. The primers of CTX-F (5'-ATTCCRGGCGAYCCGCGTGATACC-3') and CTX-R (5'-ACCGCGATATCGTTGGTG GTGCCAT-3') used to detect CTX-M ESBLs were developed in our laboratory. The isolates were also examined for SHV and TEM ESBLs by PCR amplification and sequencing with the primer pairs described previously (2). The CTX-M ESBL type was determined by sequence analysis using the primer pairs (1). The sequences were determined by direct sequencing of PCR products, and sequencing was performed on an ABI Prism 3130 Genetic Analyzer (Applied Biosystems Japan Ltd., Tokyo).

## RESULTS

### ITS-PCR patterns of GNB.

MGE analysis of the amplified products obtained from 368 isolates comprising 45 GNB species consistently showed one to four intense and sharp bands (major fragments) for each sample, ranging from 241 to 1,765 bp (Table 1). A single fragment of the same size ( $685 \pm 6$  bp) was obtained from *A. calcoaceticus* JCM6842<sup>T</sup> and *A. baumannii* JCM6841<sup>T</sup>. Two ITS-PCR patterns were observed among *Achromobacter xylooxidans*, *K. pneumoniae*, *Proteus mirabilis*, *Providencia rettgeri*, *Pseudomonas putida*, and *Stenotrophomonas maltophilia*; three patterns among *B. fragilis* group, *Enterobacter cloacae*, and *Morganella morganii*, and four patterns among *Serratia marcescens*. Nine *Salmonella* isolates belonging to six serotypes showed common strong bands at 449 and 624 bp, and one weak band at 512 bp. There were no significant differences among *Salmonella* serotype isolates. Although most of the strains studied

had unique ITS-PCR patterns at the species level, identical ITS-PCR patterns were found among *Enterobacter aerogenes* isolates, some *E. cloacae* strains, and *Klebsiella oxytoca* isolates. In addition, *Pseudomonas stutzeri* and *Ralstonia pickettii* yielded a single fragment ranging from  $591 \pm 3$  and  $594 \pm 7$  bp, respectively. For *A. xylosoxidans*, two ITS-PCR patterns were observed; type axy1 from *A. xylosoxidans* subspecies *denitrificans* JCM 5490<sup>T</sup> and type axy2 from *A. xylosoxidans* subspecies *xylosoxidans* JCM 9659<sup>T</sup>. Figure 1A shows the seven representative ITS-PCR patterns of clinically relevant GNB.

#### **ESBL-producing isolates.**

Of 116 isolates that were intermediate or resistant to the third-generation cephalosporins, 109 were suspected as ESBL-producers by the combination disk method. One hundred seven isolates (97 *E. coli*, 5 *K. pneumoniae*, 2 *K. oxytoca*, and 3 *Proteus mirabilis*) were positive for CTX-M genes, the remaining two for SHV-12 ESBL (1 isolate each *E. coli* and *K. oxytoca*). Of 107 CTX-M-positive isolates determined by PCR, 89 (83%) isolates appeared to carry gene of CTX-M-9, seven of CTX-M-15, three each of CTX-M-2 and CTX-M-14, two of CTX-M-3, and one of CTX-M-27. Two CTX-M-positive *K. oxytoca* isolates were shown to harbor the *bla<sub>oxy</sub>* gene by sequencing analysis of CTX-M gene amplification products. No isolates harboring TEM ESBL genes were found among those tested, and there were no cases of false-positive results. Overall, 98 (92%) of 107 ESBL-producing isolates were *E. coli*.

#### **Identification of GNB from positive blood culture bottles.**

A total of 259 bacteria were isolated from 255 GNB-positive blood cultures; 251

bottles (98%) contained a single bacterial species, while 4 (2%) contained polymicrobial growth. ITS-PCR analyses accurately identified 225/259 (87%) of organisms in positive blood culture bottles to the species level, while 22 isolates that showed ITS-PCR pattern of *K. oxytoca* were identified as *Enterobacter/K. oxytoca* group (Table 2). Four isolates (three *Bacteroides fragilis* group and one *Acinetobacter Iwoffii*) were not identified, because they showed novel ITS-PCR patterns that were not included in our database. Furthermore, eight organisms in mixed culture bottles were not identified because of complex ITS-PCR patterns. Overall, 228 (91%) of 251 GNB isolated from bottles that contained a single bacterial species were correctly identified at the species level directly from blood culture bottles. There were no cases of incorrect identification. CTX-M ESBL genes were detected from 20 bottles by PCR, and all ESBL-positive strains were identified as *E. coli* by ITS-PCR patterns and the culture-based method. Figure 1B shows the amplification product of the CTX-M ESBL gene and ITS-PCR pattern of CTX-M ESBL-producing *E. coli*.

Cost analysis was performed for reagents for conventional testing and molecular testing. The average cost for conventional identification of GNB ranged from \$10 to \$12. With molecular testing, testing cost is significantly lower when more than one test is processed at the same time. The cost of identifying GNB and detecting CTX-M ESBL from one sample alone would represent the maximum cost per sample, which was calculated to be \$6.50. We have calculated the cost of running two samples for identification to be \$4.80 per sample.

## DISCUSSION

The PCR assay to detect polymorphisms in the 16S-23S rRNA gene spacer region is

potentially useful for both species-level identification of coagulase-negative *Staphylococcus* species and GNB (8, 13) and strain discrimination of *S. aureus* (8) and *Clostridium difficile* (5). One issue that is critical for the successful detection of spacer variation is the choice of PCR primers. Primers were selected to target highly conserved regions in the 16S and 23S rRNA genes. To date, four primers in the 16S rRNA gene, and six primers in the 23S rRNA gene have been proposed, and some primers failed to detect spacer variation at the species or strain level (10). Jensen *et al.* (13) first demonstrated that PCR-amplified rDNA spacer polymorphisms using primers G1 (positions 1,491–1,504 based on the sequence of the *E. coli* 16S rRNA gene) and L1 (positions 21–35 based on the sequence of the *E. coli* 23S rRNA gene) were useful for identification of GNB. We used similar primers IX and II targeting positions 1487–1503 of the *E. coli* 16S rRNA gene, and positions 23–38 of the *E. coli* 23S rRNA gene, respectively. Based on the results obtained with the 368 strains tested here, length polymorphisms of the ITS region showed significant promise for identification of clinically relevant GNB.

It is not surprising that some strains belonging to different genera or species showed similar ITS-PCR patterns. In this study, *Enterobacter* species and *K. oxytoca* showed the same patterns. As these two species have been reported to show similar antibiotic-susceptibility patterns (more than 10% strains are resistant to piperacillin, third-generation cephalosporins, and tobramycin) (26), rapid species-level identification of these species may not be required for planning of antibiotic treatment. When isolates tested yielded a single band of similar length, ITS-PCR patterns alone could not be used for general differentiation of glucose non-fermenting GNB. For example, *P. stutzeri* and *R. pickettii* (591 – 594 bp), and *Pseudomonas alcaligenes* and *Pseudomonas*

*pseudoalcaligenes* (576–606 bp) showed bands of similar sizes. Although these four species strains are rarely isolated from blood cultures, as shown here and in a previous study (14), the physician would be able to implement therapy for either *Pseudomonas* (excluding *P. aeruginosa*) or *Enterobacteriaceae* infection much sooner with the ITS-PCR result than with the results of Gram staining, which would only indicate the presence of Gram-negative bacteria. To differentiate strains based on ITS-PCR products, which revealed a similar single band, conventional phenotypic methods should be performed in parallel. On the other hand, four isolates were not identified, as these strains showed novel ITS-PCR patterns. Therefore, it is necessary to continue adding new ITS-PCR patterns of isolates from clinical materials to the database, resulting in increased sensitivity.

Because our PCR-based method with universal primers amplified all kinds of bacteria, the major limitation of our methods for the direct detection of bacteria from clinical samples is mixed flora. Polymicrobial bacteremia due to GNB have been reported in 2 of 405 (1.0%) blood culture bottles (16). In our study, 4 of 255 bottles (1.6%) had two different *Enterobacteriaceae* identified in each sample by conventional methods. When electrophoresis of culture showed an unusual pattern with two or more fragments, the presence of mixed flora should be taken into consideration and the identification of bacteria may be difficult. Overall, these observations indicated that ITS-PCR followed by MGE is useful for rapid, cost-effective, and reliable species-level identification of GNB responsible for bloodstream infections. The approach described here seems also to be useful for the recognition of potentially novel infection-associated pathogens.

In recent years, CTX-M ESBL has been recognized as a growing family possessing a

high level of hydrolyzing activities, especially against cefotaxime. The present study showed that 105 (98%) of 107 ESBL-producers isolated from various clinical samples were CTX-M-type ESBL. The same results were reported by Suzuki *et al.* (23). They reported that 130 (92%) of 142 *E. coli* isolates suspected of producing ESBL were confirmed to harboring *bla*<sub>CTX-M</sub> by PCR and sequencing analysis. There are more than 80 different variants of CTX-M enzymes, which can be further classified into five different subgroups based on their amino acid sequences: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 groups (4). Of these, CTX-M-9, CTX-M1, and CTX-M-2 groups have been reported as the most common groups in Japan (23). In this study, the most common CTX-M was CTX-M-9 group (88%), followed by CTX-M-1 and CTX-M-2 group. The predominance of CTX-M-9 in our hospital is not a consistent finding worldwide, as different CTX-M-type enzymes have emerged as the predominant ESBLs in other locations (4). *K. oxytoca* may give a false-positive result in phenotypic tests for ESBL production due to hyperproduction of the chromosomally encoded K1  $\beta$ -lactamase (20). Monstein *et al.* (17) have shown that the universal *bla*<sub>CTX-M</sub> PCR amplification primers also target the almost identical K1 DNA sequence. The same results were obtained in the present study. Therefore, reports regarding CTX-M ESBL production from *K. oxytoca* by PCR should be excluded until sequencing results have been determined.

As the CTX-M gene amplicon size was very small (216 bp) and PCR products obtained from ITS-PCR ranged from 241 bp to 1765 bp, PCR-MGE enabled simultaneous detection of CTX-M gene and ITS-PCR patterns, which was both cost-effective and saved time. Poor outcome occurs when patients with serious infections (bacteremia, hospital-acquired pneumonia, peritonitis) due to ESBL-producers are treated with cephalosporins to which the responsible organism is resistant (12, 22). The provision of

PCR results regarding bacterial identification and CTX-M ESBL at the initial physician contact could result in prudent therapy. The methods described here may also be useful for detecting novel CTX-M-producing species, because CTX-M-producing *P. aeruginosa* and *S. maltophilia* have been reported previously (1). There are epidemiological implications for the detection of ESBL-producers in that this resistance may not be as apparent if the organisms are simply reported as resistant to individual cephalosporins.

In conclusion, detection of the ITS length polymorphisms by PCR-MGE is useful for rapid, reliable, and relatively cost effective species-level identification of GNB responsible for bloodstream infections. In addition, PCR-MGE seems to be a useful tool for simultaneous detection of CTX-M ESBL and ITS-PCR patterns of GNB. The main limitation of ITS-PCR identification method relies on the database and on the inter-laboratory variations. We are preparing a database with the high integrity that can be applied comprehensively to pathogenic bacteria, and our database may be shared to allow other laboratories to identify their strains via a simple web-based tool.

TABLE 1. Results of internal transcribed spacer PCR

Organism	Control strain	ITS-PCR type (no. of strains tested)	Sizes of amplified DNA fragments (bp, mean $\pm$ SD <sup>a</sup> )
<i>Achromobacter xylosoxidans</i>	JCM 5490 <sup>T</sup>	axy1 (2)	<u>436 <math>\pm</math> 1</u> , <u>683 <math>\pm</math> 4</u>
"	JCM 9659 <sup>T</sup>	axy2 (5)	<u>690 <math>\pm</math> 4</u> , 745 $\pm$ 6
<i>Acinetobacter calcoaceticus</i> - <i>baumannii</i> complex <sup>b</sup>	JCM 6841 <sup>T</sup>		
	JCM 6842 <sup>T</sup>	aba(12)	<u>685 <math>\pm</math> 6</u>
<i>Acinetobacter junii</i>	K6122	aju (1)	750 $\pm$ 4, <u>790 <math>\pm</math> 6</u>
<i>Acinetobacter lwoffii</i>	JCM 6840 <sup>T</sup>	alw (2)	740 $\pm$ 7, 760 $\pm$ 7, 815 $\pm$ 10, <u>850 <math>\pm</math> 10</u> , 910 $\pm$ 15
<i>Aeromonas hydrophila</i>	JCM 1027 <sup>T</sup>	ahy (9)	<u>562 <math>\pm</math> 7</u> , 618 $\pm$ 7, 626 $\pm$ 9, 642 $\pm$ 7, 663 $\pm$ 8
<i>Alcaligenes faecalis</i>	JCM 1474 <sup>T</sup>	afa (2)	<u>438 <math>\pm</math> 3</u> , <u>679 <math>\pm</math> 5</u>
<i>Bacteroides fragilis</i> group	ATCC 25285 <sup>T</sup>	bfr1 (18)	241 $\pm$ 2, <u>583 <math>\pm</math> 8</u> , 645 $\pm$ 7
"	K1845	bfr2 (14)	242 $\pm$ 3, <u>458 <math>\pm</math> 3</u> , <u>580 <math>\pm</math> 4</u> , 645 $\pm$ 8
"	K7144	bfr3 (10)	<u>458 <math>\pm</math> 3</u> , <u>540 <math>\pm</math> 3</u> , <u>610 <math>\pm</math> 3</u>
<i>Burkholderia cepacia</i>	K9261	bce (4)	<u>479 <math>\pm</math> 8</u> , <u>619 <math>\pm</math> 5</u> , 661 $\pm$ 5
<i>Buttiauxella agrestis</i>	JCM 1090 <sup>T</sup>	bag (1)	<u>486 <math>\pm</math> 1</u> , <u>653 <math>\pm</math> 4</u>
<i>Campylobacter jejuni</i>	K9554	cje (3)	<u>949 <math>\pm</math> 8</u>
<i>Cardiobacterium hominis</i>	K5271	cho (1)	<u>612 <math>\pm</math> 4</u>
<i>Cedecea davisae</i>	JCM 1685 <sup>T</sup>	cda (1)	<u>451 <math>\pm</math> 1</u> , <u>479 <math>\pm</math> 2</u> , <u>629 <math>\pm</math> 2</u>
<i>Chryseobacterium</i> <i>indologenes</i>	NBRC 14944 <sup>T</sup>	cin (2)	<u>743 <math>\pm</math> 5</u> , <u>1765 <math>\pm</math> 35</u>
<i>Citrobacter freundii</i>	K948	cfr (4)	<u>324 <math>\pm</math> 2</u> , <u>483 <math>\pm</math> 8</u> , <u>629 <math>\pm</math> 2</u>
<i>Citrobacter koseri</i>	K12195	cko (10)	<u>443 <math>\pm</math> 5</u> , 475 $\pm$ 4, 498, <u>605 <math>\pm</math> 3</u>
<i>Cronobacter sakazakii</i>	JCM 1233 <sup>T</sup>	csa (1)	<u>450 <math>\pm</math> 2</u> , <u>517 <math>\pm</math> 2</u>
<i>Delftia acidovorans</i>	JCM 5833 <sup>T</sup>	dac (3)	<u>756 <math>\pm</math> 5</u>
<i>Edwardsiella tarda</i>	JCM 1656 <sup>T</sup>	eta (2)	<u>434 <math>\pm</math> 5</u> , <u>529 <math>\pm</math> 6</u>
<i>Elizabethkingia</i> <i>meningoseptica</i>	NBRC 12535 <sup>T</sup>	eme (1)	<u>688 <math>\pm</math> 5</u>
<i>Enterobacter aerogenes</i>	K1235	eae <sup>c</sup> (8)	<u>291 <math>\pm</math> 6</u> , <u>447 <math>\pm</math> 5</u> , <u>595 <math>\pm</math> 4</u>

Continued



Organism	Control Strain	ITS-PCR type (no. of strains tested)	Sizes of amplified DNA fragments (bp, mean ± SD)
<i>Enterobacter cloacae</i>	ATCC 23355	ec1 <sup>c</sup> (10)	<u>294±5</u> , <u>440±6</u> , <u>591±6</u>
"	K12309	ec2 (20)	<u>295±4</u> , <u>441±6</u> , <u>529±6</u> ,
"	K12880	ec3 (11)	<u>292±4</u> , <u>438±7</u> , <u>526±7</u> , <u>593±8</u> ,
<i>Escherichia coli</i>	ATCC 35218	eco (22)	422 ± 1, 444 ± 4, <u>455 ± 5</u> , 478 ± 5, 529±4, <u>540±4</u> , 553±2
<i>Haemophilus influenzae</i>	IID983	hin (17)	<u>578 ± 5</u> , 681 ± 2, 766 ± 3, 793 ± 5, 825±9, 854±8
<i>Klebsiella pneumoniae</i>	ATCC 700603	kpn1 (14)	<u>290±4</u> , 311 ± 3, <u>439±5</u> , 467±5, <u>520±5</u> , 591±7
"	K14488	kpn2 (2)	<u>315±2</u> , <u>477±5</u> , <u>623±3</u>
<i>Klebsiella oxytoca</i>	K7	kox <sup>c</sup> (15)	<u>293±3</u> , <u>439±4</u> , <u>590±5</u>
<i>Morganella morganii</i>	JCM 1672 <sup>T</sup>	mmo1 (5)	<u>451±2</u> , <u>569±6</u> , <u>591±7</u> , <u>775±10</u>
"	K4081	mmo2 (4)	<u>562±2</u> , <u>586±3</u> , 744 ± 4, <u>778±6</u>
"	K5488	mmo3 (3)	<u>589±9</u> , 760 ± 6, <u>779±6</u>
<i>Neisseria meningitidis</i>	K15850	nme (3)	<u>732±7</u>
<i>Pantoea agglomerans</i>	JCM 1236 <sup>T</sup>	pag (2)	<u>470±1</u> , <u>487±3</u> , <u>674±6</u>
<i>Pasteurella multocida</i>	K5105	pmu (3)	<u>498±3</u> , <u>716±4</u>
<i>Proteus mirabilis</i>	JCM 1669 <sup>T</sup>	pmi1 (15)	<u>501±6</u> , 622 ± 5, 647 ± 7, 674 ± 8 830 ± 7
"	K7446	pmi2 (4)	<u>629±7</u> , <u>659±5</u> , 689 ± 4, 820 ± 9
<i>Proteus vulgaris</i>	JCM 1668 <sup>T</sup>	pvu (6)	<u>608±3</u> , 633 ± 7, 657 ± 2, 784 ± 4 812 ± 5, 865 ± 3
<i>Providencia alcalifaciens</i>	JCM 1673 <sup>T</sup>	pal (1)	<u>514±5</u> , <u>672±8</u>
<i>Providencia rettgeri</i>	JCM 1675 <sup>T</sup>	pre1 (4)	<u>702±8</u> , 732 ± 10, 756 ± 4, 787 ± 3 819 ± 8, 890 ± 12
"	K8723	pre2 (3)	<u>670±5</u> , <u>761±9</u>
<i>Pseudomonas aeruginosa</i>	K10836	pae (15)	318 ± 3, <u>560±4</u>
<i>Pseudomonas alcaligenes</i>	JCM 5967 <sup>T</sup>	pal (2)	<u>576±4</u>
<i>Pseudomonas pseudoalcaligenes</i>	JCM 5968 <sup>T</sup>	pps (2)	<u>606±3</u>
<i>Pseudomonas fluorescens</i>	JCM 5963 <sup>T</sup>	pfl (6)	421 ± 1, <u>608±3</u>

Continued

Organism	Control strain	ITS-PCR type (no. of strains tested)	Sizes of amplified DNA fragments (bp, mean $\pm$ SD)
<i>Pseudomonas putida</i>	JCM 6156	ppu1 (7)	<u>374<math>\pm</math>6</u> , 383 $\pm$ 1, 558 $\pm$ 2, 595 $\pm$ 6
"	JCM 6158	ppu2 (1)	<u>401<math>\pm</math>3</u> , <u>589<math>\pm</math>3</u>
<i>Pseudomonas stutzeri</i>	ATCC 17588	pst (1)	<u>591<math>\pm</math>3</u>
<i>Ralstonia pickettii</i>	JCM 5969 <sup>T</sup>	rpi (3)	<u>594<math>\pm</math>7</u>
<i>Salmonella enterica</i> <sup>d</sup>	ATCC 14028	sen (9)	<u>449<math>\pm</math>4</u> , 512 $\pm$ 5, <u>624<math>\pm</math>4</u>
<i>Serratia marcescens</i>	JCM 1239 <sup>T</sup>	smar1 (12)	<u>501<math>\pm</math>4</u> , <u>568<math>\pm</math>5</u>
"	ATCC 8100	smar2 (2)	<u>504<math>\pm</math>4</u> , <u>547<math>\pm</math>1</u> , <u>568<math>\pm</math>3</u>
"	K7701	smar3 (4)	<u>548<math>\pm</math>3</u> , <u>566<math>\pm</math>3</u>
"	K12077	smar4 (3)	<u>546<math>\pm</math>4</u> , <u>564<math>\pm</math>6</u> , <u>615<math>\pm</math>3</u>
<i>Sphingobacterium spiritivorum</i>	JCM 1277 <sup>T</sup>	ssp (1)	<u>474<math>\pm</math>4</u>
<i>Stenotrophomonas maltophilia</i>	JCM 1976	smal1 (16)	<u>606<math>\pm</math>8</u> , 627 $\pm$ 5, 647 $\pm$ 6
"	JCM 1975 <sup>T</sup>	smal2 (3)	<u>624<math>\pm</math>5</u> ,
<i>Vibrio vulnificus</i>	JCM 3725 <sup>T</sup>	vvu (1)	<u>540<math>\pm</math>3</u> , <u>601<math>\pm</math>3</u> , <u>661<math>\pm</math>4</u> , <u>787<math>\pm</math>9</u>

<sup>a</sup> Mean amplicon sizes were obtained from the results of three experiments for each control strain. The underlines indicate the sharp and intense fragments that were consistently observed.

<sup>b</sup> *Acinetobacter calcoaceticus-baumannii* complex included two reference strains, *Acinetobacter calcoaceticus* JCM6841<sup>T</sup> and *Acinetobacter baumannii* JCM6842<sup>T</sup>.

<sup>c</sup>ITS-PCR patterns of *Enterobacter aerogenes* strains and some *Enterobacter cloacae* strains were similar to those of *Klebsiella oxytoca*.

<sup>d</sup> Nine strains of the genus *Salmonella* included six serotypes, *S.* Paratyphi A, *S.* Paratyphi B, *S.* Choleraesuis, *S.* Typhimurium, *S.* Typhi, and *S.* Enteritidis.

TABLE 2. Results of ITS-PCR analysis and extended-spectrum  $\beta$ -lactamase PCR with positive blood culture bottles for Gram-negative bacteria

Organism (total no. of bottle <sup>a</sup> )	No. (%) of strains identified correctly at species level by ITS-PCR patterns	No. (%) of the CTX-M ESBL- producing isolates
<i>E. coli</i> (104)	104 (100)	20 (19)
<i>P. aeruginosa</i> (30)	30 (100)	0
<i>K. pneumoniae</i> (29)	29 (100)	0
<i>S. maltophilia</i> (18)	18 (100)	0
<i>E. cloacae</i> (12)	6 (50) <sup>b</sup>	0
<i>K. oxytoca</i> (10)	0 (0) <sup>b</sup>	0
<i>S. marcescens</i> (8)	8 (100)	0
<i>A. calcoaceticus</i> - <i>baumannii</i> complex (6)	6 (100)	0
<i>B. fragilis</i> (6)	3 (50)	0
<i>E. aerogenes</i> (6)	0 (0) <sup>b</sup>	0
<i>A. xylosoxidans</i> (4)	4 (100)	0
<i>C. koseri</i> (4)	4 (100)	0
<i>C. freundii</i> (3)	3 (100)	0
<i>P. mirabilis</i> (3)	3 (100)	0
<i>H. influenzae</i> (2)	2 (100)	0
<i>A. lwoffii</i> (2)	1 (50)	0
<i>B. cepacia</i> (1)	1 (100)	0
<i>E. tarda</i> (1)	1 (100)	0
<i>N. meningitidis</i> (1)	1 (100)	0
<i>P. putida</i> (1)	1 (100)	0
Polymicrobial (4)	0 (0)	0
Total (255)	225 (88%)	20 (19)

<sup>a</sup> When two or more samples obtained from the same patient were positive for the same organism, only one sample was included.

<sup>b</sup> Six *E. cloacae* isolates and six *E. aerogenes* isolates showed similar ITS-PCR

patterns to those of *K. oxytoca*. Therefore, the isolates revealed the ITS-PCR pattern of *K. oxytoca* were identified as *Enterobacter/K. oxytoca* group.



**A****B**

FIG. 1. Results of microchip gel electrophoresis of ITS-PCR products of clinically relevant Gram-negative organisms in positive blood cultures (A), and the simultaneous detection of PCR products of CTX-M ESBL gene and ITS regions obtained from *E. coli* K2588 (B). Asterisk indicates PCR product (216 bp) of the CTX-M ESBL gene, and arrows indicate DNA size markers of 100 bp (left) and 1,000bp (right). Int., Intensity.

#### REFERENCES

1. al Naiemi, N., B. Duim, and A. Bart. 2006. A CTX-M extended-spectrum  $\beta$ -lactamase in *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia*. *J. Med. Microbiol.* 55:1607-1608.
2. al Naiemi, N., B. Duim, P. H. Savelkoul, L. Spanjaard, E. de Jonge, A. Bart, C. M. Vandebroucke-Grauls, and M. D. de Jong. 2005. Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. *J. Clin. Microbiol.* 43:4862-4864.
3. Barenfanger, J., C. Drake, and G. Kacich. 1999. Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing. *J. Clin. Microbiol.* 37:1415-1418.
4. Canton R., and T. M. Coque. 2006. The CTX-M  $\beta$ -lactamase pandemic. *Current Opinion Microbiol.* 9:466-475.
5. Cartwright, C. P., F. Stock, S. E. Beekmann, E. C. Williams, and V. J. Gill. 1995. PCR amplification of rRNA intergenic spacer regions as a method for epidemiologic typing of *Clostridium difficile*. *J. Clin. Microbiol.* 33:184-187.
6. Cheng, J., L. C. Waters, P. Fortina, G. Hvichia, S. C. Jacobson, J. M. Ramsey, L. Kricka, and P. Wilding. 1998. Degenerate oligonucleotide primed-polymerase chain

reaction and capillary electrophoretic analysis of human DNA on microchip-based devices. *Anal. Biochem.* 257:101-106.

7. Eigner, U., M. Weizenegger, A.-M. Fahr, and W. Witte. 2005. Evaluation of a rapid direct assay for identification of bacteria and the *mecA* and *van* genes from positive blood cultures. *J. Clin. Microbiol.* 43:5256-5262.

8. Fujita S., Y. Senda, T. Iwagami, and T. Hashimoto. 2005. Rapid identification of staphylococcal strains from positive-testing blood culture bottles by internal transcribed spacer PCR followed by microchip gel electrophoresis. *J. Clin. Microbiol.* 43:1149-1157.

9. Goossens, H., and Grabein B. 2005. Prevalence and antimicrobial susceptibility data for extended-spectrum  $\beta$ -lactamase- and *AmpC*-producing *Enterobacteraceae* from the MYSTIC program in Europe and the United States (1997-2004). *Diagn. Microbiol. Infect. Dis.* 53:257-264.

10. Grtler, V., and V. A. Stanisich. 1996. New approaches to typing and identification of bacteria using the 16S-23S rDNA spacer region. *Microbiol.* 142:3-16.

11. Hawser, S. P., S. K. Bouchillon, D. J. Hoban R. E. Badal, P-R. Hsueh, and D. L. Paterson. 2009. Emergence of high levels of extended-spectrum- $\beta$ -lactamase -producing Gram-negative bacilli in the Asia-Pacific region: data from the study for monitoring antimicrobial resistance trends (SMART) program, 2007. *Antimicrob. Agents Chemother.* 53:3280-3284.

12. Ho, P. L., W. M. Chan, K. W. Tsang, S. S. Wong, and K. Young. 2002. Bacteremia caused by *Escherichia coli* producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. *Scand. J. Infect. Dis.* 34:567-573.

13. Jensen, M. A., J. A. Webster, and N. Straus. 1993. Rapid identification of bacteria on

the basis of polymerase chain reaction-amplified ribosomal DNA spacer polymorphisms. *Appl. Environ. Microbiol.* 59: 945-952.

14. Jordan, J. A. J. Jones-laughner, and M. B. Durso. 2009. Utility of pyrosequencing in identifying bacteria directly from positive blood culture bottles. *J. Clin. Microbiol.* 47:368-372.

15. Lewis II, J. S., M. Herrera, B. Wickes, J. E. Patterson, and J. H. Jorgensen. 2007. First report of the emergence of CTX-M-type extended-spectrum  $\beta$ -lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. *Antimicrob. Agents Chemother.* 51:4015-4021.

16. Marlowe E. M. J. J. Hogan, J. F. Hindler, I. Andruszkiewicz, P. Gordon, and D. A. Bruckner. 2003. Application of an rRNA probe matrix for rapid identification of bacteria and fungi from routine blood cultures. *J. Clin. Microbiol.* 41:5127-5133.

17. Monstein H.-J., Å. Östholm-Balkhed, M. V. Nilsson, M. Nilsson, K. Dornbusch, and L. E. Nilsson. 2007. Multiplex PCR amplification assay for the detection of *bla*SHV, *bla*TEM and *bla*CTX-M genes in *Enterobacteriaceae*. *Acta Pathol. Microbiol. Immunol. Scand.* 115:1400-1408.

18. Munson, E. L., D. J. Diekema, S. E. Beekmann, K. C. Chapin, and G. V. Doern. 2003. Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management. *J. Clin. Microbiol.* 41:495-497.

19. National Committee for Clinical Laboratory Standards. 2005. Performance standards for antimicrobial susceptibility testing; 15th information supplement (M100-S15). National Committee for Clinical Laboratory Standards, Wayne, Pa.

20. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum  $\beta$ -lactamases: a clinical update. *Clin. Microbiol. Rev.* 18:657-686.



21. Peters, R. P. H., P. H. M. Savelkoul, A. M. Simoons-Smit, S. A. Danner, C. M. J. E. Vandenbroucke-Grauls, and M. A. van Agtmael. 2006. Faster identification of pathogens in positive blood cultures by fluorescence in situ hybridization in routine practice. *J. Clin. Microbiol.* 44:119-123.
22. Schiappa, D. A., M. K. Hayden, M. G. Matushek, F. N. Hashemi, J. Sullivan, K. Y. Smith, D. Miyashiro, J. P. Quinn, R. A. Weinstein, and G. M. Trenholme. 1996. Ceftazidime-resistant *Klebsiella pneumoniae* and *Escherichia coli* bloodstream infection: a case-control and molecular epidemiologic investigation. *J. Infect. Dis.* 174:529-536.
23. Suzuki S., N. Shibata, K. Yamane, J-i. Wachino, K. Ito, and Y. Arakawa. 2009. Changes in the prevalence of extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* in Japan by clonal spread. *J. Antimicrob. Chemother.* 63:72-79.
24. Tumbarello, M., M. Sanguinetti, E. Montuori, E. M. Treccarichi, B. Posteraro, B. Fiori, R. Citton, T. D'Inzero, G. Fadda, R. Cauda, and T. Spanu. 2007. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae*: importance of inadequate initial antimicrobial treatment. *Antimicrob. Agents Chemother.* 51:1987-1994.
25. Turenne, C. Y., S. E. Sanche, D. J. Hoban, J. A. Karlowsky, and A. M. Kabani. 1999. Rapid identification of fungi by using the internal transcribed spacer 2 genetic region and an automated fluorescent capillary electrophoresis system. *J. Clin. Microbiol.* 37:1846-1851.
26. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin. Infect. Dis.* 39:309-317.